Efficacy of sonidegib in histologic subtypes of advanced basal cell carcinoma: Results from the final analysis of the randomized phase 2 Basal Cell Carcinoma Outcomes With LDE225 Treatment (BOLT) trial at 42 months - 10/03/21

Reinhard Dummer, MD ^{a, ⁎} , John T. Lear, MD ^b, Alex Guminski, MD, PhD ^c, Liang Joo Leow, MBBS, MPH&TM ^{d, e, f}, Nicholas Squittieri, MD ^g, Michael Migden, MD ^h

^a Department of Dermatology, University Hospital Zürich, University of Zürich, Zürich, Switzerland 

^b Department of Dermatology, Salford Royal National Health Service Foundation Trust, Salford, United Kingdom 

^c Department of Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia 

^d Department of Dermatology, St. Vincent's Private Hospital, Sydney, New South Wales, Australia 

^e St Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australia 

^f St Vincent's & Mater Clinical School, University of Notre Dame Australia, Sydney, New South Wales, Australia 

^g Medical Affairs Oncology, Sun Pharmaceutical Industries, Inc, Princeton, New Jersey, United States 

^h Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas, United States 

^∗Correspondence and reprint requests to: Reinhard Dummer, MD, Department of Dermatology, University Hospital Zürich, University of Zürich, Gloriastrasse 31, 8091 Zürich, SwitzerlandDepartment of DermatologyUniversity Hospital ZürichUniversity of ZürichGloriastrasse 31Zürich8091Switzerland